Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Bitcoin Dominance Backtests 60% After Two-Year Wedge Breakdown, Could Spur Altcoin Rotation

Bitcoin Dominance Backtests 60% After Two-Year Wedge Breakdown, Could Spur Altcoin Rotation

CoinotagCoinotag2025/10/06 16:00
By:Sheila Belson

  • Bearish wedge breakdown confirmed

  • 60% acts as key resistance; failure to reclaim it points to further BTC.D declines

  • Historical data shows BTC.D declines often lead to mid‑cap and low‑cap altcoin rallies

Bitcoin Dominance update: BTC.D breaks a multi‑year wedge and retests 60% resistance — monitor for altcoin rotation and trading opportunities. Read more on COINOTAG.

Bitcoin Dominance undergoes a bearish backtest, pointing to declining BTC share and rising potential for altcoin market rallies.

What is happening to Bitcoin Dominance (BTC.D)?

Bitcoin Dominance (BTC.D) has broken below a two‑year ascending broadening wedge and is currently retesting prior support around the 60% level as resistance. This bearish backtest increases the probability that BTC.D declines further, which historically aligns with rotating liquidity into altcoins.

How did the wedge breakdown occur and why does it matter?

Weekly data shows an ascending broadening wedge that formed for more than two years and recently broke to the downside. The wedge breakdown signals structural weakness in Bitcoin’s market share. If BTC.D fails to reclaim the wedge boundary at ~60%, analysts project a move toward 50%–48%, which would materially increase altcoin market opportunity.

#Altcoins $BTC.D is in a bearish backtest.
It previously broke out of an ascending broadening wedge that had been forming for more than 2 years.
Bullish for Altcoins. Very bullish‼️ pic.twitter.com/To7t8pg7fG

— 𝕄𝕠𝕦𝕤𝕥𝕒𝕔ⓗ𝕖 🧲 (@el_crypto_prof) October 7, 2025

Why does a BTC.D decline favor altcoins?

Declines in Bitcoin Dominance historically reflect capital rotation from Bitcoin into altcoins. When BTC.D moves lower, mid‑cap and small‑cap tokens often receive disproportionate inflows, producing multi‑month rallies. This trend is driven by traders seeking higher beta and by liquidity redistributions across exchanges and decentralized markets.

What has historical data shown?

Past cycles indicate that a sustained BTC.D decline of 8–12 percentage points commonly aligns with an altcoin season lasting several weeks to months. Market data from previous cycles (public exchange and on‑chain records) show heavier volume and price appreciation concentrated in mid‑cap and low‑cap sectors during these phases.

Frequently Asked Questions

What level should traders watch on BTC.D?

Watch the 60% level as near‑term resistance; if BTC.D remains below 60% and continues lower, targets near 50%–48% become more probable. Use weekly confirmations and volume to validate the move.

How soon could an altcoin season begin if BTC.D falls further?

Altcoin rotations can begin within days to weeks after a confirmed BTC.D downtrend. Historically, traders reposition once weekly confirmations and liquidity flows indicate sustained dominance shifts.

Key Takeaways

  • Breakdown confirmed: BTC.D has broken a multi‑year ascending broadening wedge, signaling structural weakness.
  • 60% retest critical: The 60% area is now resistance; failure to reclaim it points to possible declines to 50%–48%.
  • Altcoins likely benefit: Historical cycles show BTC.D declines often coincide with mid‑cap and low‑cap altcoin rallies; traders should prepare with risk management.

Conclusion

Bitcoin Dominance’s wedge breakdown and current bearish backtest at 60% increase the probability of capital rotation into altcoins. Traders and market participants should monitor weekly confirmations, on‑chain liquidity flows, and mid‑cap token activity. COINOTAG will continue to track BTC.D and report developments to inform positioning and risk management.

In Case You Missed It: Bitcoin ETFs May See Institutional Inflows After $5.48B Volume as BlackRock’s IBIT Nears $100B
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Anthropic files for IPO: lost $4.2 billion last year, revenue grew 12x to $4.6 billion, risk section warns of "threats to human survival"

Anthropic's IPO prospectus reveals that its spending on computing power and infrastructure will reach $7.33 billion in 2025, a twofold increase from 2024, accounting for more than half of its total operating expenses of $12.65 billion. The company plans to continue investing over $500 billion in the future. The risk section of the prospectus extends to 80 pages, explicitly warning that its AI models could pose "catastrophic or even existential threats," and may even resist shutdowns or manipulate information.

华尔街见闻•2026/09/29 01:01

Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business

Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.

华尔街见闻•2026/09/29 00:51

AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose

This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.

华尔街见闻•2026/09/29 00:26